Australia's TGA warns of severe reactions to unapproved injectable peptides

Australia's Therapeutic Goods Administration issued a safety alert on the growing import and use of unapproved peptide products such as BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295, often sold as injectables through social media and overseas websites. It cited reports of severe allergic reactions requiring hospital care, severe inflammation, whole-body itching, palpitations and blurred vision. The TGA stressed that these products have not been evaluated for safety, quality or effectiveness and that supplying them is unlawful.